Inclusion Criteria:

• Have a diagnosis of Type I diabetes with an interval of < 90 days between initial diagnosis and the first dose of study drug.
• Have a written documentation of the diabetes Mellitus diagnosis, including the date of diagnosis, must be obtained from the diagnosing physician
• Currently require insulin treatment for Type I Diabetes Mellitus
• Be willing to remain at the study center for at least 6 hours on each day of dosing (8 consecutive days)
• BMI < 32

Exclusion Criteria:

• Have significant systemic infections during the 6 weeks before the first dose of study drug (i.e., infection requiring hospitalization, major surgery, or IV antibiotics to resolve, other infections e.g., bronchitis, sinusitis, localized cellulitis, candidiasis, or urinary tract infection)
• Have hepatitis
• Have used any potent immunosuppressive agent (e.g., systemic high-dose corticosteroids on a chronic basis, methotrexate, cyclosporine, or anti-TNF agents) within the 30 days before signing the informed consent and not expected to require such treatment within 3 months after the last dose of study drug
• Have used any atypical antipsychotic drug within the 30 days before signing informed consent and not expected to require such treatment during the study
• Have received a vaccine within 30 days before signing informed consent and not expected to require a vaccine during the dosing period or the 14 days after the last dose of study drug
• Have previously received otelixizumab or any other anti-CD3 monoclonal antibody
• Have previously received an anti-lymphocyte monoclonal antibody, such as ATG, Rituxan® or Campath®
• Have undergone any major surgical procedure within 30 days of first dose of study drug
• Have prior allergic reaction, including anaphylaxis, to any human, humanized, chimeric or rodent antibody